



Department
of Health &
Social Care

Projects funded by DHSC through the UK Vaccine Network Project Phase 2.0

Last updated September 2025

The following document includes all projects funded by the UK Vaccine Network during Phase 2.0 of the programme (2023 to 2028).

Contents

Projects delivered through the Innovate UK managed SBRI Stage 1 Competition	2
Projects delivered through BactiVac managed competition to develop bacterial vaccines and vaccinology	4
Projects delivered through Medicines and Healthcare products Regulatory Agency (MHRA).....	6
Projects delivered through UK Health Security Agency (UKHSA) managed programme to develop vaccines for epidemic diseases.....	7
Projects delivered through Engineering and Physical Sciences Research Council (EPSRC) managed Future Manufacturing Research Hub competition.....	8

Projects delivered through the Innovate UK managed SBRI Stage 1 Competition

Project title	Lead research organisation	Cost
LPS conjugate for Coxiella	University of Oxford	£1,500,213.00
Clinical development of DIOS-HFVac3: A pre-clinically effective multivalent vaccine for Lassa fever virus, Marburg virus, and Sudan ebolavirus	DIOSynVax Limited	£1,775,729.00
Serological Correlates of Vaccine Protection – Marburg/Nipah/Plague/Q-Fever	Medicines and Healthcare products Regulatory Agency	£1,996,230.00
Preclinical development of A CD8 T-Cell Priming Vaccine Against Chikungunya Virus	Emergex Vaccines Holding Limited	£1,798,109.00
A bivalent vaccine against the two major arthritogenic alphaviruses: Chikungunya and Mayaro	University of Oxford	£893,278.00
Heat proofing Immunity: Pioneering a Thermally Resilient Ensilicated mRNA-LNP Vaccine Platform	Ensilicated Technologies Limited	£1,777,048.00
An mRNA vaccine for Plague: design to clinical efficacy testing	NeoVac Limited	£1,986,118.00
Rapid, Synthetic, Scaled Manufacture and Exemplification of an Injectable DNA Zika Vaccine	University of Nottingham	£1,863,677.00
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.	ConserV Bioscience Limited	£680,034.00
Development of an orally administered Enterovirus 68 vaccine	iosBio Limited	£476,563.00
An mRNA vaccine for plague	University of Oxford	£1,972,284.00

Project title	Lead research organisation	Cost
UNICOR-v, a pancoronavirus vaccine	ConserV Bioscience Limited	£975,768.00
Development of a VLP vaccine for the emerging viral pathogen Enterovirus D68	University of Leeds	£670,801.00
Automated and digitalised RNA process-in-a-box for rapid outbreak-response disease-agnostic RNA vaccine/therapeutic development and manufacturing at high-quality and low cost	University of Sheffield	£1,999,084.00
Novel OMV vaccine platform for quick response to Disease X	Abera Bioscience AB	£1,816,160.00
Sudan Ebolavirus - Vaccine testing against Sudan Ebolavirus	University of Oxford	£1,423,733.00
Establishment of an advanced preclinical model for Rift Valley fever (RVF) virus for the assessment of vaccine efficacy and licensure pathway via the Animal Rule.	UK Health Security Agency	£1,726,183.00
CCHFv vaccine for LMICs - transition from preclinical to clinical studies	Oxford Expression Technologies	£1,415,760.00
EML-VAC: Clinical evaluation of a multivalent replicon vaccine against Ebola, Marburg and Lassa viruses	Imperial college London	£1,951,602.00
Establishing Marburg Vaccine Development and Manufacturing Capability in Africa: Collaboration between Public Health Vaccines (PHV) and Institut Pasteur de Dakar (IPD) for the Technology Transfer of PHV's Clinical-Stage rVSV Marburg Vaccine Candidate	Public Health Vaccines LLC	£1,885,659.00
Advancing Vaccine Development: Harnessing Multiple Antigenic Epitopes for Crimean-Congo	Uganda Virus Research Institute	£1,979,981.00

Project title	Lead research organisation	Cost
Hemorrhagic Fever in Humans and Animals		
Marburg virus - A first in human clinical trial to deliver a vaccine against Marburg virus Disease	University of Oxford	£1,999,275.00
A bivalent vaccine to reduce the risk of Nipah virus outbreaks	The Pirbright Institute	£1,488,875.00

Projects delivered through BactiVac managed competition to develop bacterial vaccines and vaccinology

Project title	Lead research organisation	Cost
Formulation and evaluation of the immunogenicity of a hexavalent <i>Neisseria meningitidis</i> vaccine targeted for low- and middle-income countries (LMICs) and travellers	Techinvention Lifecare Pvt. Ltd., India	£36,533.00
Scale-Up and production of a <i>Bordetella pertussis</i> Bifunctional Vaccine/Adjuvant Candidate for Clinical Trials	Ciencias Biológicas. Instituto de Biotecnología y Biología Molecular de la Facultad de Ciencias Exactas de la Universidad Nacional de La Plata CONICET, Argentina	£50,000.00
Development of a broadly protective glycoconjugate vaccine against outbreak-prone <i>Klebsiella pneumoniae</i>	Department of Biomolecular Sciences, University of Urbino, Italy	£48,000.00

Project title	Lead research organisation	Cost
Evaluation of novel adjuvants to improve bacterial vaccines during immunosenescence	Faculty of Health and Medical Sciences (FHMS), University of Surrey	£40,362.29
Mucosal vaccination with adenovirus-vectored and mRNA vaccines against Plague.	Oxford Vaccine Group, Department of Paediatrics, University of Oxford	£46,749.33
Analysis of vaccine antigen expression in a diverse collection of Streptococcus pyogenes isolates	Imperial College London	£39,987.51
Establishing a Novel approach to Plague Vaccine testing - A Feasibility Study of an Attenuated Yersina pestis Vaccine Challenge Model	Imperial College London	£37,522.53
Immunogenic screening of novel diphtheria vaccine candidates effective against the toxin variants and nontoxic Corynebacterium diphtheriae strains causing invasive infections	Northumbria University	£63,852.00
Binding and functional serum antibodies to Shigella antigens and the risk of shigellosis in a cohort of Zambian children in the first 3 years of life	Centre for Infectious Disease Research in Zambia	£49,651.22
Advancing the understanding of cell mediated immunity to natural Shigella infection through functional immunological approaches	Kamuzu University of Health Sciences	£77,066.00
Evaluating the use of novel adjuvants to improve the efficacy of a novel gonococcal Outer Membrane Vesicle vaccine	University of Oxford	£59,900.00
Nasal Spray Device Testing for a Universal Pneumococcal Vaccine in Preparation for Phase 1 Clinical	Abera Bioscience AB	£70,000.00

Project title	Lead research organisation	Cost
Trial		
Enabling early life anti-carbohydrate antibody responses against bacterial infection	University of Exeter	£64,973.75
Gut Microbiome and Mucosal antibody Responses in Shigella Infection: Insights to inform implications for Vaccine Development	Centre for Infectious Disease Research in Zambia	£64,195.51
An mRNA vaccine for Q-fever	Oxford Vaccine Group	£64,878.02
Mechanisms behind Salmonella Typhi Breakthrough Infections in Children Vaccinated with Typhoid Conjugate Vaccine (TCV)	Aga Khan University	£67,023.00
Developing bioconjugate candidate vaccines against a major enteric pathogen using structure-guided enzyme engineering.	Nile University	£62,500.00

Projects delivered through Medicines and Healthcare products Regulatory Agency (MHRA)

Project title	Lead research Organisation	Cost
Supporting epidemic and pandemic preparedness by expanding the portfolio of research reagents for emerging viruses	The Centre for Infectious Disease Reagents-Medicine and Healthcare products Regulatory Agency (MHRA)	£932,439.00

Projects delivered through UK Health Security Agency (UKHSA) managed programme to develop vaccines for epidemic diseases

Project title	Lead research organisation	Cost
Development of PNA Capability for Priority Pathogens	UK Health Security Agency	£585,000.00
Development of Multiplex pAn-Virus Inhibition (MAVI) assays`	UK Health Security Agency	£478,409.00
Preclinical model expansion for henipahviruses	UK Health Security Agency	£234,103.00
Development of GMP LassaVacc: Progression towards clinical trials	UK Health Security Agency	£107,073.00
Development of an X-ray inactivated whole virus vaccine for Zika	UK Health Security Agency	£206,964.00
Qualification of Live Virus neutralisation assays	UK Health Security Agency	£435,000.00
Advancement of a cost-effective MVA based Hantavirus vaccine (HantaVacc)	UK Health Security Agency	£1,041,319.00

Projects delivered through Engineering and Physical Sciences Research Council (EPSRC) managed Future Manufacturing Research Hub competition

Project title	Lead research organisation	Cost
Future Vaccine Manufacturing Hub	Imperial College London	£9,998,374.00
Vax-Hub	University College London	£9,626,941.78
The Chanjo Hub	Imperial College London	£6,223,075.00
The UK-South East Asia Vaccine Manufacturing Hub	University of Sheffield	£7,199,509.69